Showing results (1-10 of 487) with videos related to
Sort By:
Pageof 49
Cancer Chemotherapy and Pharmacology|January 1, 1988
Development of alkylating agent-resistant human tumor cell linesB A Teicher, E FreiAnticancer Research|November 1, 1996
Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cellsG Chen, B A Teicher, E FreiCancer Biochemistry Biophysics|January 29, 1999
Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotypeG Chen, B A Teicher, E FreiCancer Letters|December 9, 1994
Long-term persistence and cytokinetics of human tumor cells in vitro following high-dose alkylating agent exposureS A Holden, B A Teicher, E FreiCancer Chemotherapy and Pharmacology|January 1, 1996
Postlabeling detection of DNA adducts of antitumor alkylating agentsG H Zhou, B A Teicher, E FreiInternational Journal of Cancer|March 1, 1996
High-dose therapy/stem cell support: comparison of mice and humansB A Teicher, D Northey, J Yuan, et al.Cancer Chemotherapy and Pharmacology|January 1, 1995
A preclinical model for sequential high-dose chemotherapyS A Holden, B A Teicher, L J Ayash, et al.Seminars in Oncology|April 1, 1991
Modulation of alkylating agents by lonidamine in vivoB A Teicher, S A Holden, T S Herman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Acute in vivo resistance in high-dose therapyB A Teicher, G Ara, S R Keyes, et al.Cancer Chemotherapy and Pharmacology|January 1, 1993
Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studiesE Frei, S A Holden, R Gonin, et al.Pageof 49